Background
==========

Current trends in cancer treatment focus to \"targeted therapy\", referring to a new generation of drugs designed to interfere with specific molecular targets that are necessary to maintain malignant phenotype, progression or metastasis \[[@B1]\]. Protein kinases constitute promising classes of cancer targets as some specific inhibitors have shown clinical benefit in patients \[[@B2],[@B3]\]. CK2 is involved in the tumor cell adaptive response and protection against apoptosis \[[@B4]\]. It is uniformly deregulated 3- to 7-fold in different cancer types \[[@B5]\] and has been associated with aggressive tumor behavior in human head and neck carcinoma \[[@B6]\]. E7 viral oncoprotein phosphorylation by CK2 plays an important role on HPV malignant properties \[[@B7]\]. Although no previous clinical trials with CK2 inhibitors have been reported so far, promising preclinical results indicate that it could be a good molecular target for cancer therapy \[[@B8]\].

CIGB-300 is a cyclic peptide that impairs CK2 phosphorylation after intracellular delivery. It behaves as pro-apoptotic both on HPV-positive and -negative tumor cell lines. Intralesional injections of the drug induced a vigorous antitumor effect on HPV-positive solid tumors in mice \[[@B9]\]. Therefore, it was hypothesized that local CIGB-300 injections could exhibit clinical benefit in patients with cervical malignancies.

Being the first-in-human application of CIGB 300 or any CK2 inhibitor, the trial reported here was done to investigate the safety and tolerability of this peptide-based drug after local injections. Besides, efficacy signs were also explored in order to provide an early proof-of-principle for CIGB-300 as a modality of targeted cancer therapy in cervical malignancies.

Methods
=======

The study followed the principles of the Declaration of Helsinki for investigations in humans. It was approved by the Ethics and Scientific Committees of the participant institutions and by the Cuban Regulatory Authority.

Patients with colposcopical and cytological suspect of HSIL or microinvasive cervical cancer were recruited at specialized services from seven gyneco-obstetric hospitals throughout Havana and other provinces. They were then evaluated at the National Reference Center for Cervical Cancer at the \"Clodomira Acosta\" Hospital, where the eligibility criteria were verified. Product administrations and evaluations took place, as in-patients, at the National Center for Toxicology, in a specialized facility for clinical Pharmacology studies.

Patient Eligibility
-------------------

Patients were included if they were 18 to 65 years-old, had histological diagnosis of HSIL or epidermoid microinvasive cervical cancer (FIGO Classification Stage 1A1)\[[@B10]\], with larger diameter ≥ 3 mm by video-colposcopy, corresponding with major changes or infiltrating stage according to the International Federation of Cervical Pathology and Colposcopy \[[@B11]\], and gave their written, informed consent to participate. Exclusion criteria were to have received chemotherapy or surgical, ablative, radiant, or immunomodulator treatment, up to 3 months before inclusion, psychiatric dysfunctions, pregnancy and breast-feeding, chronic diseases such as asthma, epilepsy, autoimmune diseases, hypertension, anemia, acute systemic or genital tract infections, renal, hepatic and cardiovascular disorders

Study Design and Treatment Plan
-------------------------------

The design was an open, uncontrolled, dose-escalating trial. The four dose levels (14, 70, 245 and 490 mg) were tested sequentially. The protocol previewed that the next dose level would be undertaken after the safety of the previous one was assured when no severe adverse events (AE) occurred up to 20 days after the first administration. Sample size for each group was previewed as between 7 and 10 patients. This N range assured that if no severe adverse reaction appeared, the probability of its occurrence would be less than 20%, with an 80%--90% confidence interval. Since patients of the same group were treated the same days, the exact number of subjects in each group was finally determined by practicalities such as the number of patients recruited that week.

CIGB-300 was synthesized and supplied by the Center for Genetic Engineering and Biotechnology in 245 mg vials, as a lyophilized powder. It was reconstituted with 1 mL of water for injection and subsequent dilutions were prepared to a final volume of 1 mL for groups I and II that received less than 245 mg per dose. Groups III and IV received one and two vials per administration, respectively.

One milliliter containing the corresponding drug dose was evenly distributed among four previously defined quadrants on the cervical lesion area. Injections were approximately 2 mm deep and were given for 5 consecutive days. Fifteen days after treatment cessation all patients underwent conization by loop electrosurgical excision procedure (LEEP). Concomitant interventions could be taken to manage the AE, according to established clinical practices. Since allergic-like reactions appeared with the lower dose levels, prophylactic antihistaminic medication (50 mg intramuscular diphenhydramine) was given 20 minutes before CIGB 300 injections to groups III and IV.

Evaluation
----------

Pretreatment evaluation included a detailed history, physical and colposcopical examinations, and HPV testing. Besides, electrocardiogram, hematological counts, blood chemistry, coagulation and cervix microbiological studies were done. Twenty-four hours after the fifth CIGB-300 administration and 15 days after treatment cessation these evaluations were repeated. Additionally, patients were followed clinically and colposcopically at 3, 6, 9, and 12 months after the conization. Papanicolau\'s test was done at these moments as well.

Since the main purpose of the trial was to evaluate the product\'s safety, local and systemic AE were carefully screened up. A colposcopic examination of the whole cervix area was carefully performed daily during the consecutive 5-day drug regimen, 24 hours after the last administration and 15 days later. Likewise, systemic toxicity was evaluated during 24 hours after each CIGB-300 administration, including cardiovascular monitoring during the injections and vital signs measurements (temperature, heart and respiratory frequencies, and blood pressure) 30 min. after the end of the injection, then every hour during 4 hours and every 4 hours thereafter.

The medical terminology for AE and their severity classification (in grades) used were those of the Cancer Therapy Evaluation Program, Common Terminology criteria \[[@B12]\]. In general, this classification consists in 5 grades: (1) mild if no therapy is necessary, (2) moderate if specific treatment is needed, (3) severe when hospitalization or its prolongation was required, (4) very severe if a reaction was potentially life-threatening, and (5) when contributed to the patient\'s death.

A qualitative assessment was used to classify the causal relationship as definite, probable, possible or doubtful \[[@B13]\]. A reaction was classified as \"definite\" if (1) followed a reasonable temporal sequence after drug administration; (2) followed a known pattern of response to the drug; (3) could not be explained by concurrent disease or other drugs; and (4) was confirmed by improvement upon drug removal and by reappearance on re-challenge. It was considered as \"probable\" if it had criteria (1), (2), (3) and was confirmed on drug suspension but not on re-challenge. A reaction was defined as \"possible\" if followed a reasonable time sequence to the drug administration, but could also be explained by concurrent disease or other drugs. Finally, a reaction that was more likely related to factors other than the suspected drug was classified as doubtful.

Colposcopical evaluations were done using a video colposcopy device (Mediscope, Medison, Korea) with a calibrated rack to standardize imaging distance and illumination. Lesions were examined by two different specialists after applying 5% acetic acid for 3 min. They were described according to the Barcelona 2002 classification \[[@B11]\] and their morphometric analysis was done with validated software for quantitative digital image evaluation (MADIP^®^V.4; Institute of Cybernetics, Mathematics and Physics, Havana)

Histological analyses were performed on colposcopically directed biopsies from abnormal areas taken before treatment and afterwards in the cone specimen. Permanent sections were subsequently prepared, stained with hematoxylin-eosin and finally reviewed by two different pathologists who classified the lesions according to the FIGO Classification.

The presence of HPV DNA in biopsies was examined before and after CIGB-300 treatment by PCR using a pair of L1-consensus primers (GP5+/GP6+) \[[@B14]\]. The HPV DNA detection limit was about 310 viral copies. Additional PCR with specific HPV-16 and -18 primers was performed for typing \[[@B15]\] and HPV DNA levels were normalized with those corresponding to β-globin as housekeeping gene.

Response Criteria and Clinical Activity
---------------------------------------

The total lesion area (TLA) was the parameter evaluated for colposcopical response. Response was defined according to the RECIST criteria \[[@B16]\]. Complete response was considered as disappearance of all high grade lesions; partial response if at least a 30% TLA decrease was observed; stable disease if changes were within -30% and + 20% regarding initial TLA; progressive disease meant at least a 20% TLA increase.

The histological response was based on the lesions phase changes. A complete response was defined as the absence of high grade lesions 15 days after drug administration; partial response when a down-staging of the high grade lesion occurred, and progression if there was up-staging.

Statistics
----------

It was not an objective of the study to compare the effect of the different CIGB-300 doses among them but to test each one in terms of tolerability and a preliminary efficacy evaluation. Therefore, dose groups were sequential and not the product of randomization.

Continuous variables were analyzed for normal distribution using the Shapiro-Wilk\'s test. They are presented as mean ± standard deviation (SD) or median ± interquartile range (QR). Categorical variables are presented as proportions. The correlation between the number of local AE and the total dose was estimated using the Pearson\'s correlation coefficient. The level of significance chosen was 0.05.

Results
=======

Patient Characteristics and Dosing History
------------------------------------------

Eighty patients from the seven participating recruiting centers were evaluated from January to July 2006. Of them, 31 were enrolled. Their demographic and baseline characteristics are outlined in Table [1](#T1){ref-type="table"}. Age ranged from 20 to 54 years and lesion area between 18 and 319 mm^2^. Most of the lesions (16; 52%) were carcinoma *in situ*; 14 (45%) were CIN and there was one microinvasive carcinoma. HPV DNA was detected in 22/28 biopsies (79%; 3 samples were not useful for PCR). All were HPV 16 except for one HPV 18 and two non 16/non 18 types.

###### 

Individual patient data

  -----------------------------------------------------------------------------------------------------------------------------------------
  **Patient No**.   CIGB-300\   Age   Total lesion area (mm^**2**^)   Histological diagnosis   HPV status                            
                    (mg)                                                                                                             
  ----------------- ----------- ----- ------------------------------- ------------------------ ------------ -------------- --------- ------
  1                 14          28    289.1                           187.1                    CIN III      CIN III        16        16

  2                 14          42    186.9                           117                      CIN III      MIC            16        16

  3                 14          35    165.3                           126.05                   CIN III      CIN III        Neg       Neg

  4                 14          33    128.6                           69.59                    CIN III      CIN III        16        16

  5                 14          33    17.7                            13.4                     MIC          CIN III        Neg       Neg

  6                 14          31    103.3                           0                        CIN III      Koilocytosis   16        Neg

  7                 14          43    93.2                            45.8                     CIN III      CIN III        16        16

  8                 14          40    62.3                            17.1                     CIN III      CIN III        16        Neg

  9                 70          34    64.8                            19.6                     CIN III      CIN III        16        Neg

  10                70          52    72.8                            5.1                      CIN II       Koilocytosis   16        16

  11                70          30    55.9                            21.5                     CIN II       CIN II         Neg       Neg

  12                70          54    36.8                            7.6                      CIN II       CIN II         Neg       Neg

  13                70          36    39.6                            0                        CIN II       CIN I          16        Neg

  14                70          20    36.1                            0                        CIN III      Koilocytosis   Neg       16

  15                70          27    73.3                            38.4                     CIN III      CIN III        16        Neg

  16                70          27    93.6                            34.1                     CIN III      CIN III        N16-N18   Neg

  17                245         31    219                             134                      CIN III      CIN III        16        16

  18                245         40    80.7                            5                        CIN III      CIN III        16        16

  19                245         33    87.8                            77                       CIN III      CIN III        16        Neg

  20                245         26    176                             8.11                     CIN III      CIN III        N.D.      N.D.

  21                245         40    85                              0                        CIN III      CIN III        18        18

  22                245         21    30.2                            0                        CIN III      Neg            N.D.      N.D.

  23                245         26    64.8                            0                        CIN III      Koilocytosis   N.D.      N.D.

  24                490         41    247                             38                       CIN II       CIN III        Neg       Neg

  25                490         29    319                             77                       CIN II       CIN III        16        Neg

  26                490         31    213                             38                       CIN II       MIC            16        Neg

  27                490         33    23                              5                        CIN III      CIN II         16        16

  28                490         39    215                             73                       CIN III      CIN III        16        N.D.

  29                490         46    30.3                            2.1                      CIN III      CIN III        N16-N18   Neg

  30                490         40    249                             55                       CIN III      CIN III        16        16

  31                490         42    144                             38                       CIN III      CIN III        16        16
  -----------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CIN II-III (cervical intraepithelial neoplasia, grade II or III), MIC (microinvasive carcinoma), Neg: Negative, N16-N18: Non-16 Non 18, ND (not determined)

The treatment schedule was completed in 30 patients (97%). One did not conclude the assigned scheme (490 mg per dose, group IV), due to a transient vasovagal syndrome with loss of consciousness that was classified as a severe event (grade 3). She received only 77 mg of the drug at the first application and the interruption was permanent.

Local and Systemic Toxicity
---------------------------

All patients experimented some local or systemic AE. A total of 409 events were recorded, 337 (82%) mild, 71 (17%) moderate and only one AE was classified as severe.

The most frequent local AE were bleeding, pain on lower abdomen, hematoma, ulcer, necrosis, erythema, and edema on the injection site (Table [2](#T2){ref-type="table"}). There was a significant correlation with respect to the total dose received and the number of local AE (r^2^= 0.469, *p*= 0.008). All local AE were grade 1 except for 2 ulcers in group II, 2 ulcers, 2 hematoma and 2 necrosis in group III, and 2 hematoma and necrosis in group IV, which reached grade 2. Twenty-two patients had either local or systemic grade 2 AE. The colposcopic examination 15 days after CIGB-300 treatment evidenced a complete recovery of all the local AE.

###### 

Frequency and distribution of the local adverse events (percents refer to the total number of events within each group)

  --------------------------------------------------------------------------------------------------------------------------
  Local Events                    Group I\    Group II\                  Group III\                Group IV\
                                  (14 mg)     (70 mg)                    (245 mg)                  (490 mg)
  ------------------------------- ----------- -------------------------- ------------------------- -------------------------
  Bleeding                        9 (47.4%)   22 (57.9%)                 5 (14.7%)                 16 (39.0%)

  Pain in lower abdomen           0           6 (15.8%)                  10 (29.4%)                8 (19.5%)

  Hematoma                        0           3 (7.9%)                   7 (20.6%); g2: 1 (2.9%)   4 (9.8%); g2: 1 (2.4%)

                                                                                                   

  Ulcer or superficial necrosis   0           6 (15.8%); g2: 6 (15.8%)   3 (8.8%); g2: 3 (8.8%)    6 (14.6%); g2: 4 (9.8%)

  Erythema *in situ\**            2 (10.5%)   0                          3 (8.8%)                  6 (14.6%)

  Edema *in situ\**               4 (21.0%)   0                          3 (8.8%)                  1 (2.4%)

  Vaginal burning                 2 (10.5%)   0                          2 (5.9%)                  0

  Spontaneous peeling             1 (5.3%)    1 (2.6%); g2: 1 (2.6%)     0                         0

                                                                                                   

  Pain in situ\*                  1 (5.3%)    0                          0                         0

  Color change at puncture site   0           0                          1 (2.9%)                  0

                                                                                                   

  **Total**                       **19**      **38**                     **34**                    **41**
  --------------------------------------------------------------------------------------------------------------------------

\*: *In situ*events referrer to the localization of such events at the site of injection. All events are grade 1 (mild) if not specified; g2: grade 2 (moderate).

Table [3](#T3){ref-type="table"} lists the clinically relevant systemic toxicities observed during the study. The most frequent were allergic-like reactions including rash, facial edema, itching, hot flashes, extensive bumps, localized cramps and tachycardia. The rate of these AE decreased with the subsequent CIBG 300 administrations (data not shown). Prophylactic antihistaminic medication greatly ameliorated some of the systemic allergic-like AE in cohorts III and IV (localized rash and localized bumps) (Table [3](#T3){ref-type="table"}). Four vasovagal syndromes were observed; one of them was grade 3 since the patient lost her consciousness transiently (1 min). Its association to CIGB-300 was not demonstrated.

###### 

Frequency and distribution of the systemic events occurred at each dose level

  ----------------------------------------------------------------------------------------------------
  Systemic Events                         Group I\     Group II\      Group III\   Group IV\      
                                          (14 mg)      (70 mg)        (245 mg)     (490 mg)       
  --------------------------------------- ------------ -------------- ------------ -------------- ----
  Itching                                 8 (14.6%)    18 (25.0%)     29 (25.9%)   29 (32.3%)     84

  Hot flashes                             12 (21.8%)   14 (11.7%)     8 (7.1%)     8 (8.9%)       42

  Localized rash                          3 (5.4%)     21 (17.5%)     6 (5.4%)     8 (8.9%)       38

  Localized facial edema                  9 (16.4%)    6 (5.0%)       8 (7.1%)     13 (14.4%)     36

  Bumps                                   0            12 (10.0%)     17 (15.2%)   6 (6.7%)       35

  Extensive rash                          2 (3.6%)     0              21 (18.8%)   5 (5.6%)       28

  Cramps                                  3 (5.4%)     2 (1.7%)       11 (9.0%)    6 (6.7%)       22

  Headache                                3 (5.4%)     2 (1.7%)       4 (3.6%)     2 (2.2%)       11

  Metallic flavor                         4 (7.3%)     6 (5.0%)       1 (0.9%)     0              11

  Tickling or tingling                    5 (9.1%)     6 (5.0%)       0            0              11

  Tachycardia                             0            7 (5.8%)       3 (2.7%)     0              10

  Tinnitus                                0            7 (5.8%)       0            0              7

  Nausea                                  0            3 (2.5%)       1 (0.9%)     3 (3.3%)       7

  Facial erythema                         0            7 (5.8%)       0            0              7

  Palpitations                            0            2 (1.7%)       1 (0.9%)     2 (2.2%)       5

  Hypertension                            3 (5.4%)     1 (0.8%)       0            1 (1.1%)       5

  Vasovagal syndrome                      0            g2: 2 (1.7%)                g3: 2 (2.2%)   4

  Dizziness                               1 (1.8%)     2 (1.7%)       0            0              3

  Tremors                                 0            0              0            3 (3.3%)       3

  Vomiting                                0            2 (1.7%)       0            0              2

  Fast breathing                          1 (1.8%)     0              0            0              1

  Abdominal pain                          1 (1.8%)     0              0            0              1

  Arrhythmia                              0            0              0            1 (1.1%)       1

  Hypotension                             0            0              1 (0.9%)     0              1

  Posture-related tremor in lower limbs   0            0              0            1 (1.1%)       1

  Red eyes                                0            0              1 (0.9%)     0              1

                                                                                                  

  Total                                   55           120            112          90             
  ----------------------------------------------------------------------------------------------------

There were no differences between baseline and post-treatment blood counts, serum chemistry results, coagulation parameters and electrocardiograms (data not shown).

Efficacy analysis
-----------------

Individual efficacy results are shown in Table [1](#T1){ref-type="table"} and summarized in Table [4](#T4){ref-type="table"}. TLA decreased in all patients at colposcopy 15 days after CIGB-300 treatment. Colposcopic response was evidenced in 28/31 patients (90%), six of them (19.4%) complete. Response rates were above 75% in all groups. Histological analyses indicated that 19.3% of the patients (6/31) experienced full regression after treatment while 25.8% (8/31) had histological grade down-staging. Responses were 10/16 (62.5%) for cases with carcinoma and 5/9 (55.6%) for patients with CIN. HPV status became undetectable in 48% (10/21) of the initially HPV-positive patients from all dose cohorts. One patient was not evaluated after treatment.

###### 

Efficacy evaluation of CIGB-300 administration.

  ---------------------------------------------------------------------------------------
                                  Group I\      Group II\     Group III\    Group IV\
                                  (14 mg)       (70 mg)       (245 mg)      (490 mg)
  ------------- ----------------- ------------- ------------- ------------- -------------
  TLA\          Initial (mm^2^)   15.7 ± 10.4   7.6 ± 2.7     10.0 ± 7.8    14.5 ± 15.5
  (mean ± SD)                                                               

                Final (mm^2^)     9.9 ± 19.6    2.8 ± 3.9     1.4 ± 14.0    5.0 ± 5.9

                \% Reduction      41.6 ± 41.3   74.6 ± 36.2   95.4 ± 61.2   81.3 ± 19.7

                                                                            

  Responders    Colposcopy        6/8 (75.0%)   8/8 (100%)    6/7 (85.7%)   8/8 (100%)

                Histology         1/8 (12.5%)   3/8 (37.5%)   2/7 (28.6%)   0/8 (0.0%)

                HPV status        2/6 (33.3%)   4/5 (80.0%)   1/4 (25.0%)   3/6 (50.0%)
  ---------------------------------------------------------------------------------------

Long term follow-up
-------------------

None of the patients showed confirmed lesion recurrence during the 12-months follow-up. There were no late adverse events either. Interestingly, 4 patients became pregnant, two of them with previous infertility history, with successful, normal neonates.

Discussion
==========

CIGB-300, a novel inhibitor of the CK2 phosphorylation, was safe and well tolerated in this study. No severe drug-related adverse reactions were observed. Intralesional application of CIGB-300 at a daily dose range from 14 to 490 mg through a consecutive-5 day regimen seems to be a safe approach. The dose range and therapeutic regimen were selected according to an extrapolation made from previous toxicological (data not published) and pharmacodynamic studies in animal models. It was not an objective of the study to compare the effect of the different CIGB-300 doses among them but to test each one in terms of tolerability and a preliminary efficacy evaluation. Although neither the MTD nor DLT were found, the most frequent systemic and local toxicities produced by the intralesional administration of CIGB-300 were identified,

The appearance of some transient systemic \"allergic-like\" events could be explained by a potential histamine release from local mastocytes. Accordingly, prophylactic antihistaminic medication of patients exposed to the higher dose levels ameliorated the systemic localized rash and bumps. As CIGB-300 inhibits CK2 phosphorylation, inducing apoptosis on the target cells, mastocyte death and the subsequent histamine release to the circulation should not be discarded and merits further investigation. However, other drugs such as interferons \[[@B17]-[@B19]\], which induce apoptosis by other mechanisms that exclude CK2, have been also locally administrated on the cervix without systemic \"allergic-like\" reactions. Alternatively, this syndrome could be related to CIGB 300\'s molecular structure, composed by several predominantly positively charged aminoacids that make it a very basic peptide and, therefore, behave as a potential histamine releaser \[[@B20]\].

The vasovagal events (n = 4), including the only grade 3 AE observed in the highest dose group, do not seem to be drug-related but rather associated to the mode of application. Vasovagal events have been reported during uterine cervix manipulation with different techniques \[[@B21]\].

The local toxicity, as evidenced by the total number of these adverse events, was dose-dependent. Importantly, cervix examination 15 days after treatment showed that all these local AE had completely disappeared. Thus, the short-lasting of the local AE observed make this approach safe to treat cervical malignancies.

The standard treatments for HSIL patients, such as LEEP, laser, cold knife conization and cryotherapy yield satisfactory results. However, these procedures are not exempt of complications and undesired effects such as cervical obstruction, which is mostly linked to fertility limitations \[[@B22]\]. Events of this magnitude were not observed during the intralesional CIGB-300 administration and the genital area integrity was preserved. In fact, four pregnancies were achieved, two of them in previous apparently infertile women.

Products such as imiquimod, administered in a gel formulation has been extensively used to treat intraepithelial lesions and genital warts \[[@B23]\], but local adverse reactions leading to treatment interruption in some patients have been also reported \[[@B24]\]. In the present study, neither the local nor systemic CIGB 300-related toxicity lead to treatment interruption, at least with this therapeutic regimen. Importantly, long-term follow-up indicated that neither local nor systemic CIGB-300-related toxicity appeared in patients after 3, 6 and 12 months of completion the drug administration.

The promising antitumor effect of CIGB-300 found in preclinical studies, lead to the hypothesis that this pro-apoptotic peptide could exhibit anti-neoplastic effect on cervical malignancies when administered directly on the transformed cervix epithelium. The results obtained seem consistent with the initial hypothesis. For instance, the colposcopic end-point demonstrated a significant response rate in the entire CIGB-300 dose range as evidenced by the TLA reduction and the responder rates in all the cohorts after a short period of time (15 days). Further studies should determine whether longer treatment or follow-up periods are required for maximal efficacy. Similarly and equally important is that CIGB-300 treatment lead to a full histological regression in 19% of the patients. This means that CIGB-300 can be able to exhibit a beneficial effect in terms of the cure or reduction of the initial lesion. According to the natural history of the disease, spontaneous regression of NIC II and III after several months is found in 43% and 32% of the patients, respectively \[[@B25]\]. Contrarily, the histological and colposcopic regression rates observed in this study seem to be drug-related as they occurred in a very short period (15 days). Additionally, no recurrences appeared during one-year follow up. However, efficacy was not the main objective of this study. Therefore such results can just be taken as preliminary. It is additionally difficult to evaluate each case according to histology since the initial biopsy was taken from the apparently more representative zone of the lesion but the final biopsy comprises the whole lesion, so this last evaluation was more exhaustive. Future placebo-controlled studies are needed to asses this criterion since these lesions are usually heterogeneous and not treatment-related changes in histological degree in the same patient can occur.

HPV status has been considered as a robust and predictive biomarker of NIC recurrence and evolution to cancer in many clinical trials \[[@B26],[@B27]\]. The result of this biomarker evaluation in this study showed that CIGB-300 exhibited an objective effect on virus presence. Forty-eight percent of initially HPV-positive patients experienced a complete virological response in the residual lesion after CIGB-300 administration. Although not all the cervix area was checked for HPV infection after drug administration, the fact that undetectable HPV levels were verified at the colposcopically directed biopsy is of great interest. The anti-HPV response observed in some patients could be reasonably explained by a potential apoptotic effect that eliminated the HPV-transformed cells during the consecutive 5-day CIGB-300 regimen.

Other molecular biomarkers (apoptosis mediators, CK2 phosphorylation status) were not studied because the second biopsy was taken 15 days after the last administration to coincide with the therapeutic cone. At that moment it is unlikely that these pharmacodynamic markers would have given any significant result since their changes are transiently regulated. An additional biopsy, close to end of treatment (day 5 or 6) would had been necessary for that purpose. However, this intervention was not ethically feasible and at the same time could have influence on the clinical outcome two weeks later.

This report describes the first clinical trial where a drug has been used to target the CK2 phosphorylation domain. The data reinforce the concept that CK2 phosphorylation represents a target with perspectives for cancer therapy, provide an early proof-of-principle of clinical benefit of a CK2 inhibitor to treat cervical malignancies, and suggest that CIGB-300 could represent a candidate drug for targeted cancer therapy.

Conclusion
==========

The CIGB-300 is a peptide-based drug that was safe and well tolerated when administered by intralesional injections. Neither a specific maximum-tolerated dose nor dose-limiting toxicity was identified, but given the efficacy signs observed at all dose levels tested, the total dose range from 14 to 490 mg is recommended for phase 2 trials. CIGB-300 treatment indicated clinical activity, as evidenced by the colposcopy, histology and the effective anti-HPV response. Such clinical effects should be confirmed in further controlled trials.
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